β-Arrestin2 (βarr2) is an adaptor protein that interacts with numerous signaling molecules and regulates insulin sensitivity. We reported previously that βarr2 was abundantly expressed in mouse pancreatic β-cells, and loss of βarr2 leads to impairment of acuteand late-phase insulin secretion. In the present study, we examined the dynamic changes of β-cell mass in barr2-deficient (barr2 -/-) mice in vivo and explored the underlying mechanisms involved. barr2
understood. Identification of key signal molecules involved in regulating β-cell mass is, thus, essential to reveal potential therapeutic targets in diabetes.
β-Arrestin2 (βarr2), an adaptor protein ubiquitously expressed in cells, modulates G-protein-coupled receptor desensitization and internalization (5) (6) (7) . It also functions as a scaffold and mediates the strength and duration of a series of cellular signaling pathways, including modulation of peripheral insulin sensitivity (8) (9) (10) . We reported previously that βarr2 was expressed abundantly in mouse pancreatic β-cells, and its expression was significantly decreased in obese and diabetic mouse models. Loss of βarr2 led to impairment of acute-and late-phase insulin secretion with β-cell mass tending to decrease in barr2-null mice (11) . β-cell mass could exist within the normal glucose tolerance stage (4) . However, the initiation of β-cell loss in humans is difficult to determine, due to the unavailability of current in vivo tracing techniques for β-cell mass measurement. In addition, the exact mechanisms underlying the loss of β-cell mass are not fully inTRODUCTiOn Type 2 diabetes (T2D) is caused by relative insulin deficiency due in part to the reduction of pancreatic β-cell mass (1-3). The relative β-cell deficits at the onset of diabetes and impaired glucose tolerance found at autopsy were 64% and 21%, respectively, indicating that loss of
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Pancreases were removed from 16-wk-old barr2 +/+ and barr2 -/-mice, immediately weighed, fixed and embedded. To determine the count and area of islets, 8-10 randomly chosen sections per mouse that were separated by at least 100 μm were stained with hematoxylin and eosin (H&E). The entire pancreatic sections were scanned using a Nikon Eclipse Ni-E Microscope (Nikon), and a tile image of the tissue section was generated using the NIS-Elements AR 4.20 (Nikon). The fractional area of the islet in the pancreas, islet count per unit pancreatic area (islet density) and islet size were manually quantified using Image-Pro Plus 6.0 (Media Cybernetics), as described previously (21) . The average of all the sections was taken as a measure for the entire organ. The total islet mass was calculated as pancreatic weight × mean fractional pancreatic islet area. For immunofluorescence analysis, pancreatic sections were incubated overnight at 4°C with guinea pig anti-insulin antibody (Abcam), followed by staining with secondary goat anti-guinea pig antibody conjugated with Alexa Fluor 488 (Invitrogen). Sections were imaged using a Zeiss AxioImager Standard Microscope (Carl Zeiss).
To analyze cell replication, barr2 The roles of βarr2 in the modulation of cell mass have been reported in smooth muscle and hepatic stellate cells (12, 13) . βarr2 aggravated atherosclerosis after carotid injury through mechanisms involving smooth muscle cell proliferation (12) and exacerbated hepatic fibrosis induced by porcine serum through its effect on hepatic stellate cell proliferation (13) , suggesting a role of βarr2 regulation of cell mass expansion under environmental stress. Interestingly, Ravier et al. reported recently that knocking out βarr2 in female mice decreased the β-cell mass (14) . However, how β-cell mass changes upon βarr2 deletion and its mechanism in regulating β-cell mass still remain largely unknown.
In the current study, using noninvasive bioluminescence imaging (BLI), we traced the dynamics of β-cell loss in mice with βarr2 deletion during the progression of impaired glucose tolerance and explored the underlying mechanisms. As overnutrition is becoming the leading risk factor of T2D, discovering molecules that protect β-cells against glucolipotoxicity is of great importance to the prevention and treatment of T2D.
MATERiALS AnD METHODS

Animals and Glucose Tolerance Test
barr2 knockout mice (barr2 -/-) were generated and identified as described previously (15, 16 Figure S1 ). Mice were fed either a normal chow diet (20% kcal protein, 10% kcal fat and 70% kcal carbohydrate; Slaccas Co.) or a high-fat diet (HFD) (20% kcal protein, 45% kcal fat and 35% kcal carbohydrates; Research Diets) from 6 wks of age. They were housed at 23°C ± 1°C under an artificial
RESULTS
Generation and Characterization of MiP-TF-aarr2 -/-Mice
To trace the effect of βarr2 on β-cell mass longitudinally in vivo, MIP-TF-barr2
-/-mice were generated with luciferase expressed exclusively in β-cells. The MIP-TF overexpression in β-cells did not affect fasting glucose level and glucose tolerance in the mice (Supplementary Figure S2) . However, knocking out βarr2 resulted in impaired glucose tolerance ( Figures 1A, B ) and a defect in glucose-stimulated insulin secretion in these mice under HFD condition ( Figure 1C ). by bioluminescence intensity increased with the growth of mice fed a chow diet. β-cell mass reached a plateau at 20 wks, 1.9-fold higher than the mass at 4 wks ( Figure 2C ). This effect was more pronounced when MIP-TF-barr2
mice were fed a HFD, with a 7.5-fold increase in β-cell mass at 16 wks ( Figure 2D ). HFD feeding also induced an increase in β-cell mass in MIP-TF-barr2
-/-mice. However, the increase was much less pronounced, at about half that in MIP-TF-barr2
mice. The expansion of β-cell mass in MIP-TF-barr2 -/-mice ceased at 12 wks, which was much earlier than that in their littermate controls ( Figure 2D ). To confirm the BLI results above, H&E staining was performed on pancreatic sections from 16-wk-old barr2 +/+ and barr2 -/-mice fed both diets ( Figure 3A ).
Compared with their littermate controls, HFD-fed barr2 -/-mice also manifested a significant decrease in islet mass, which is associated with decreased islet area and islet density (all P < 0.05), but not by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The membranes were incubated overnight at 4°C with anti-phosphorylated JNK (p-JNK) antibody, anti-total JNK antibody (Cell Signaling Technology), anti-Cyclin D2 antibody (Cell Signaling Technology) and anti-p21 antibody (Millipore), followed by incubation with corresponding HRP-conjugated secondary antibodies. Signals were detected using Fujifilm Luminescent Image Analyzer LAS4000 System (Fujifilm).
BLi BLI was performed using a Lumazone Imaging System (Roper Scientific Photometrics) as described previously (23) . MIP-TF mice were anesthetized with isoflurane (1.5% in 98.5% O 2 ) and injected with 126 mg/kg of D-luciferin (15 mg/mL in phosphate-buffered saline) intraperitoneally. Then, mice were placed in the supine orientation in a light-tight chamber, and a gray-scale reference image was obtained under low-level illumination. Bioluminescent images were captured 12 min after luciferin injection with an integration time of 3 min. Isometric regions of interest were drawn over the location corresponding to the pancreas for quantification using MAG Biosystems Software 7.6 (MAG Biosystems). Luciferase activity is presented in photon intensity per second. Bioluminescence attenuation was adjusted as described previously by Yong et al. (17) .
Statistical Analysis
Data are expressed as mean ± standard error of the mean. Statistical analysis was performed with GraphPad Prism 5 for Windows (GraphPad software), and significance was calculated by Student t test or analysis of variance (ANOVA) and followed with Bonferroni correction as appropriate. For all analyses, P values were two-tailed, and P < 0.05 was considered statistically significant. We next examined the effect of βarr2 on β-cell viability in glucolipotoxicity, a condition that occurred during HFD feeding in mice. As expected, exposure of islets or INS-1 (832/13) cells to high levels of glucose or palmitate led to cell death compared with that of their respective controls (Figures 5A, B) . Deletion of βarr2 in islets increased the cell death compared with wild-type islets ( Figure 5A ), whereas overexpression of βarr2 in INS-1 (832/13) cells greatly alleviated the cell death ( Figures  5B, C and Supplementary Figure S4) . Taken together, our results suggested a role of βarr2 in protection of β-cells from high glucose-and FFA-induced cell death. Moreover, in INS-1 (832/13) cells with βarr2 overexpression, the mRNA level of cyclin D2 increased by 2.5-fold and the mRNA level of p21 decreased to 0.69-fold ( Figure 4D ), both of which encode cell cycle-related proteins that play roles in release of the G 1 brake on cell cycle progression. Similar trends of changes in protein levels could be observed in the two genes ( Figure 4E ). No changes could be viewed in the mRNA expression of other G 1 phase regulators (cyclin D1, Cdk4 and Cdk6), G 1 /S phase regulators (cyclin E1, cyclin E2 and Cdk2), S/G 2 phase regulators (cyclin A2 and Cdk1), and Cdk inhibitors (p18 and p27) ( Figure 4D ). Figure S3) .
Overexpression of aarr2-Protected
Loss of aarr2 Resulted in Decreased islet Cell Proliferation in Mice
βarr2 promotes proliferation in smooth muscle cells and hepatic stellate cells (12, 13) . Thus, we examined the effect of βarr2 on β-cell proliferation. As shown in Figure 4A , percentages of both BrdU-and Ki67-positive cells were decreased significantly in islets from barr2 -/-mice, exhibiting only 40% or 53% of the positive rate of their barr2
littermates, respectively (both P < 0.05; Figure 4B ). In contrast, overexpression of βarr2 in INS-1 (832/13) cells inhibitor, dose-dependently abolished the above effect. In contrast, the cytoprotective effects of βarr2 on high glucose-and FFA-induced death were diminished dose-dependently in the presence of JNK1 ( Figure 6E ). Taken together, these observations suggested that βarr2 modulates β-cell survival through the regulation of proapoptosis JNK pathway.
DiSCUSSiOn
In the present study, using a real-time tracing imaging technique, we characterized the dynamic changes of β-cell mass in barr2-null mice under HFD conditions from 4 to 20 wks and provided in vivo evidence demonstrating that validated the expression pattern of MKK7 observed in the array analysis ( Figure 6B) . Moreover, exposure of INS-1 (832/13) to high glucose or FFA led to the phosphorylation of JNK, whereas overexpression of βarr2 in the cells diminished the JNK activation ( Figure 6C ), suggesting a role of βarr2 in the regulation of the JNK signaling pathway. To confirm findings in islets, the gain-and loss-of-function experiments were performed in the β-cell line. As shown in Figure 6D , knocking down of βarr2 in INS-1 (832/13) cells with shRNA significantly aggravated the high glucose-and FFA-induced cell death to 1.8-fold (glucose) and 1.6-fold (FFA). The addition of SP600125, a JNK a microarray analysis was performed to compared the gene expression between islets isolated from barr2 -/-and barr2
mice. In total, 819 genes were found to be changed significantly in the barr2-null islets. Among them, 558 genes were upregulated and 261 genes were downregulated. As shown in Figure 6A , components in the JNK/mitogen-activated protein kinase (MAPK) signaling pathway were significantly altered in barr2 deficiency of βarr2 in mice led to much earlier and more severe decompensation of β-cell mass under HFD (Figure 2) . Moreover, we provide evidence supporting the novel roles of βarr2 in protection of β-cells from glucotoxicity-and lipotoxicity-induced cell death ( Figure 5 ) through inhibition of proapoptosis JNK pathway activation ( Figure 6 ) and in regulation of cell proliferation through cyclin D2 and p21 expression modulation ( Figure 4 ). Revealing novel roles and mechanisms of βarr2 in regulating dynamic β-cell mass changes is essential to provide information necessary for the development of new therapy strategies for T2D. It is well known that β-cell mass changes during the development and progression of T2D (1) (2) (3) (4) . Mass quantification with noninvasive approaches is important for basic science and clinical studies. However, quantification of β-cell mass in vivo is relatively difficult due to the lack of reliable and noninvasive biomarkers for cells (24) . Recently, the use of in vivo imaging techniques including positron-emission tomography (PET) and single-photon emission computed tomography (SPECT) with isotope-labeled ligands [such as 18 
F-fluoropropyl-(+)-DTBZ and 111
In-labeled exendin] have been utilized in the field of human β-cell image studies (25) (26) (27) . Likewise, BLI has been widely used with luciferase transgenic mice to evaluate β-cell mass under both normal and pathological conditions (17, 28) . BLI is advantageous because it saves the animals from being killed and allows sequential studies in the same animal. In contrast to other imaging methods, BLI additionally provides quantifiable data with high throughput and inherently low background. However, a drawback of limited tissue penetration in BLI makes it impossible to apply to humans. Nevertheless, the lower cost of BLI compared with other imaging methods and good correlation with pancreatic β-cell mass makes BLI highly useful for studies in small animals.
In the present study, to trace the effect of βarr2 loss on the changes of β-cell mass during mouse growth in real of βarr2 deletion on glucose-stimulated insulin secretion are controversial (11, 14) . This discrepancy may result from the islets isolated from different mice, as while we used islets from 12-wk-old male mice, Ravier et al. used islets from 6-to 7-month-old female mice. Further studies may be needed to explore the possibility. The failure of β-cells to compensate for the lost mass under metabolic stress observed in barr2 -/-mice indicates the role of βarr2 in regulation of β-cell mass.
One mechanism underlying the loss of β-cell mass in HFD-fed barr2 -/-mice is likely the consequence of reduced β-cell proliferation via modulation of cell cycle regulation. We showed in the study that both BrdU-and Ki67-positive cells were decreased significantly in islets with βarr2 deletion. Overexpression of βarr2 increased the proportion of cells in the S and G 2 /M phases of the cell cycle with concomitant upregulation of cyclin D2 and attenuation of p21 expression in INS-1 (832/13) cells (Figure 4 ). Both cyclin D2 and p21 are cell cycle-related proteins involved in regulating release of the G 1 brake and entry of cell cycle (31, 32) . Cdk inhibitor p21 functions as a molecular brake during β-cell expansion and is upregulated during pregnancy and mitogen stimulation to avoid excessive proliferation (33) (34) (35) (36) . Cyclin D2 is the major D-type cyclin in β-cells and plays a vital role in the regulation of adult β-cell proliferation (31, 37) . Knocking out cyclin D2 in mice resulted in a four-fold reduction in β-cell mass and led to development of impaired glucose tolerance or even diabetes in these mice (38, 39) . In contrast, overexpression of cyclin D2 in human islets increased BrdU-positive cells (40) . While cyclin D2 might be a regulator driving adaptive β-cell proliferation, it is currently unclear how βarr2 manipulates cyclin D2 transcription in β-cells. It is known that activation of the insulin receptor/Akt signaling pathway was associated with β-cell proliferation (41) . βarr2 has been reported to enhance insulin-stimulated Akt activity in mouse liver, skeletal muscle and those of Ravier et al. reporting with female mice (14) when we prepared our manuscript. Moreover, our histological study revealed that decreased islet density, rather than mean islet size, was the major outcome in HFD-fed barr2 -/-mice ( Figure 3 ). Similar phenomena were reported from autopsy findings in nondiabetic adults (21) and in carriers with TCF7L2 rs7903146 (T/T), a risk allele for T2D (30) . Taken together, our results indicate that loss of small islets in barr2 -/-mice contributes to the failure to adapt β-cell mass under metabolic stress. However, the data reported on the effect time, barr2 -/-mice were interbred with MIP-TF mice. Consistent with previous findings, HFD induced an adaptive increase of β-cell mass in mice (17) . During a prolonged observation period, we noticed a declining trend in β-cell mass after 16 wks in HFD-fed mice, supporting the transition from compensation to decompensation during increasing metabolic demand (29) . Knocking out βarr2 led to an earlier and more severe decompensation of β-cell mass in mice fed a HFD (Figure 2 ). Our in vivo findings are in agreement with fixed our specimen findings ( Figure 3 ) and by Moreover, we showed in the present study that βarr2 protected β-cells from glucolipotoxicity-induced cell apoptosis. The antiapoptosis effects for βarr2 are in agreement with several previous studies D2 (42). It is, thus, speculated that the effect of βarr2 on cyclin D2 transcription might be through the Akt/FoxO1a pathway. Further studies are needed to explore that possibility. adipose tissue (10) . In INS-1E cells, activation of Akt is associated with phosphorylation of FoxO1a and prevents FoxO1a from translocation into the nucleus, thus releasing transcription repression of cyclin . Data were presented as fold-change over cells infected with scrambled shRNA (D, white bar) or GFP (E, white bar) (n = 4). *P < 0.05, **P < 0.01, versus indicated group. Muk, mitogen-activated protein kinase upstream protein kinase; Mkk7, mitogen-activated protein kinase kinase 7. Jnk, c-Jun N-terminal kinase.
